The drugstore posted a .6% drop in June same-store sales, while
during the month.
As a result, shares of Rite Aid tanked 9% to $1.40 during morning trading -- a disappointing result, only a day after the drugstore finally
with the New York Stock Exchange's share price listing requirement.
While Walgreen was able to offset softness in seasonal items and other discretionary purchases through prescription sales, Rite Aid wasn't so lucky.
Its pharmacy-store sales rose 1.4%, hurt by new generic drug introductions, while front-end sales sank 4.5%.
Total sales for the month also fell 2.5% to $1.97 billion.
Last week, Rite Aid refinanced most of its debt that was set to expire in September 2010. The company had a $145 million loan and $1.75 billion credit facility maturing in September 2010. After the refinancing, its only significant debts due before 2012 are its borrowings under its accounts receivable securitization programs. Those borrowings are due in September.
Copyright 2009 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. AP contributed to this report.